Stimuli-free programmable drug release for combination chemo-therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Combinational chemotherapy requires targeted delivery and programmable multi-drug release for enhanced efficacy.
• Current treatment strategies have limitations in achieving both targeted delivery and controlled multi-drug release simultaneously.
• Developing effective systems for dual-drug delivery is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To develop SiO2-based self-decomposable nanoparticulate systems for targeted delivery of chemotherapeutic and immunotherapeutic agents.
• To achieve programmable, sequential drug release without external stimuli by manipulating drug loading configurations.
• To evaluate the efficacy and safety of the developed system in targeting FAT1-expressing colon cancer cells both in vitro and in vivo.

Main Methods:

• Fabrication of SiO2-based nanoparticulate systems for drug encapsulation.
• Programming sequential drug release by altering drug loading configurations within nanoparticles.
• In vitro assessment of nanoparticle targeting and drug release kinetics.
• In vivo studies in animal models to evaluate tumor reduction and systemic toxicity.

Main Results:

• Demonstrated specific binding of nanoparticles to FAT1-expressing colon cancer cells.
• Achieved sequential release of dual drugs (chemotherapeutic and immunotherapeutic) with distinct time intervals.
• Observed significant reduction in tumor weight (1/350) and moderate increase in body weight in treated rats compared to controls.
• Showcased enhanced synergistic effects of combined drugs, leading to improved therapeutic outcomes and reduced systemic toxicity.

Conclusions:

• The developed SiO2 nanoparticulate system offers a feasible and effective method for targeted combination chemotherapy with programmed drug release.
• This approach enhances drug efficacy and minimizes toxicity, presenting a promising strategy for advanced cancer treatment.
• The system's ability to control sequential drug delivery provides a novel platform for optimizing synergistic therapeutic effects.